Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
| Revenue (Most Recent Fiscal Year) | $234.04M |
| Net Income (Most Recent Fiscal Year) | $-323.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -138.30% |
| Net Margin (Trailing 12 Months) | -138.43% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -45.78% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.80 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.93 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.62 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 104.22M |
| Free Float | 98.90M |
| Market Capitalization | $372.05M |
| Average Volume (Last 20 Days) | 1.51M |
| Beta (Past 60 Months) | 1.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |